BR112015017381A2 - agentes analgésicos oculares tópicos - Google Patents

agentes analgésicos oculares tópicos

Info

Publication number
BR112015017381A2
BR112015017381A2 BR112015017381A BR112015017381A BR112015017381A2 BR 112015017381 A2 BR112015017381 A2 BR 112015017381A2 BR 112015017381 A BR112015017381 A BR 112015017381A BR 112015017381 A BR112015017381 A BR 112015017381A BR 112015017381 A2 BR112015017381 A2 BR 112015017381A2
Authority
BR
Brazil
Prior art keywords
analgesic agents
topical eye
topical
topical ocular
eye
Prior art date
Application number
BR112015017381A
Other languages
English (en)
Inventor
C David Karen
C Appell Kenneth
R Hellberg Mark
Gadd Martha
G Klimko Peter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015017381A2 publication Critical patent/BR112015017381A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Abstract

resumo patente de invenção: "agentes analgésicos oculares tópicos". a presente invenção refere-se ao uso oftálmico tópico de certas 2,4-diamino-1,3-triazinas substituídas para prevenir ou aliviar a dor ocular em pacientes. composição farmacêutica ocular tópica é também descrita.
BR112015017381A 2013-02-13 2014-02-13 agentes analgésicos oculares tópicos BR112015017381A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764166P 2013-02-13 2013-02-13
PCT/US2014/016234 WO2014127116A1 (en) 2013-02-13 2014-02-13 Topical ocular analgesic agents

Publications (1)

Publication Number Publication Date
BR112015017381A2 true BR112015017381A2 (pt) 2017-07-11

Family

ID=50190796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017381A BR112015017381A2 (pt) 2013-02-13 2014-02-13 agentes analgésicos oculares tópicos

Country Status (14)

Country Link
US (2) US9187468B2 (pt)
EP (1) EP2956118A1 (pt)
JP (1) JP2016511246A (pt)
KR (1) KR20150119082A (pt)
CN (1) CN104994839A (pt)
AU (1) AU2014216273A1 (pt)
BR (1) BR112015017381A2 (pt)
CA (1) CA2901208A1 (pt)
CL (1) CL2015002188A1 (pt)
MX (1) MX2015009414A (pt)
PH (1) PH12015501538A1 (pt)
RU (1) RU2015138686A (pt)
WO (1) WO2014127116A1 (pt)
ZA (1) ZA201600425B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511246A (ja) * 2013-02-13 2016-04-14 ノバルティス アーゲー 局所眼用鎮痛薬
CN115300218A (zh) 2015-03-26 2022-11-08 密歇根大学董事会 用于冷冻麻醉和镇痛的施用装置
FR3044227B1 (fr) * 2015-11-30 2017-11-24 Pharmaleads Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502143B1 (en) * 1990-09-07 1995-11-08 Universidad De Alicante Composition for treating ocular pain
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
JP2016511246A (ja) * 2013-02-13 2016-04-14 ノバルティス アーゲー 局所眼用鎮痛薬

Also Published As

Publication number Publication date
RU2015138686A (ru) 2017-03-17
AU2014216273A8 (en) 2015-07-16
PH12015501538A1 (en) 2015-10-05
US20140228338A1 (en) 2014-08-14
ZA201600425B (en) 2017-05-31
WO2014127116A1 (en) 2014-08-21
CN104994839A (zh) 2015-10-21
MX2015009414A (es) 2015-09-24
US20160089375A1 (en) 2016-03-31
EP2956118A1 (en) 2015-12-23
CA2901208A1 (en) 2014-08-21
KR20150119082A (ko) 2015-10-23
US9187468B2 (en) 2015-11-17
CL2015002188A1 (es) 2015-12-11
JP2016511246A (ja) 2016-04-14
AU2014216273A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112015018289A2 (pt) piridona amidas como moduladores de canais de sódio
BR112016000825A8 (pt) compostos moduladores de sulfonamidas dos canais de sódio, composição farmacêutica, e uso dos mesmos
BR112015026325A2 (pt) dosagem oral de compostos glp-1
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014001880A2 (pt) derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112014001118A2 (pt) combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
EA201692276A1 (ru) Комбинации тиотропия бромида, формотерола и будесонида для лечения хобл
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112015017381A2 (pt) agentes analgésicos oculares tópicos
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.